Toggle navigation
Search
Tree View
MeSH on Demand
MeSH 2024
About
Suggestions
Contact Us
Bevacizumab
MeSH Descriptor Data 2023
Details
Qualifiers
MeSH Tree Structures
Concepts
MeSH Heading
Bevacizumab
Tree Number(s)
D12.776.124.486.485.114.224.060.375
D12.776.124.790.651.114.224.060.438
D12.776.377.715.548.114.224.200.438
Unique ID
D000068258
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068258
Scope Note
An anti-VEGF humanized murine monoclonal antibody. It inhibits
VEGF RECEPTORS
and helps to prevent
PATHOLOGIC ANGIOGENESIS
.
Entry Term(s)
Avastin
Bevacizumab-awwb
Mvasi
Pharm Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Registry Number
2S9ZZM9Q9V
See Also
Receptors, Vascular Endothelial Growth Factor
Public MeSH Note
2016; BEVACIZUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2015, and under ANTIBODIES, MONOCLONAL 2002-2011
History Note
2016 (2002)
Date Established
2016/01/01
Date of Entry
2015/07/10
Revision Date
2018/11/02
Allowable Qualifiers
administration & dosage (AD)
adverse effects (AE)
analysis (AN)
biosynthesis (BI)
blood (BL)
cerebrospinal fluid (CF)
chemistry (CH)
classification (CL)
drug effects (DE)
economics (EC)
genetics (GE)
history (HI)
immunology (IM)
isolation & purification (IP)
metabolism (ME)
pharmacokinetics (PK)
pharmacology (PD)
physiology (PH)
poisoning (PO)
radiation effects (RE)
therapeutic use (TU)
toxicity (TO)
ultrastructure (UL)
urine (UR)
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Immunoproteins [D12.776.124.486]
Immunoglobulins [D12.776.124.486.485]
Antibodies [D12.776.124.486.485.114]
Antibodies, Monoclonal [D12.776.124.486.485.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
Abciximab [D12.776.124.486.485.114.224.060.125]
Adalimumab [D12.776.124.486.485.114.224.060.250]
Alemtuzumab [D12.776.124.486.485.114.224.060.313]
Basiliximab [D12.776.124.486.485.114.224.060.344]
Bevacizumab [D12.776.124.486.485.114.224.060.375]
Brentuximab Vedotin [D12.776.124.486.485.114.224.060.438]
Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
Cetuximab [D12.776.124.486.485.114.224.060.750]
Daclizumab [D12.776.124.486.485.114.224.060.766]
Denosumab [D12.776.124.486.485.114.224.060.782]
Gemtuzumab [D12.776.124.486.485.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.486.485.114.224.060.794]
Ipilimumab [D12.776.124.486.485.114.224.060.798]
Natalizumab [D12.776.124.486.485.114.224.060.813]
Nivolumab [D12.776.124.486.485.114.224.060.829]
Omalizumab [D12.776.124.486.485.114.224.060.844]
Palivizumab [D12.776.124.486.485.114.224.060.860]
Panitumumab [D12.776.124.486.485.114.224.060.864]
Ranibizumab [D12.776.124.486.485.114.224.060.868]
Trastuzumab [D12.776.124.486.485.114.224.060.875]
Ustekinumab [D12.776.124.486.485.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Blood Proteins [D12.776.124]
Serum Globulins [D12.776.124.790]
Immunoglobulins [D12.776.124.790.651]
Antibodies [D12.776.124.790.651.114]
Antibodies, Monoclonal [D12.776.124.790.651.114.224]
Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
Abciximab [D12.776.124.790.651.114.224.060.125]
Adalimumab [D12.776.124.790.651.114.224.060.250]
Alemtuzumab [D12.776.124.790.651.114.224.060.375]
Basiliximab [D12.776.124.790.651.114.224.060.407]
Bevacizumab [D12.776.124.790.651.114.224.060.438]
Brentuximab Vedotin [D12.776.124.790.651.114.224.060.469]
Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
Cetuximab [D12.776.124.790.651.114.224.060.750]
Daclizumab [D12.776.124.790.651.114.224.060.766]
Denosumab [D12.776.124.790.651.114.224.060.782]
Gemtuzumab [D12.776.124.790.651.114.224.060.790]
Inotuzumab Ozogamicin [D12.776.124.790.651.114.224.060.794]
Ipilimumab [D12.776.124.790.651.114.224.060.798]
Natalizumab [D12.776.124.790.651.114.224.060.813]
Nivolumab [D12.776.124.790.651.114.224.060.829]
Omalizumab [D12.776.124.790.651.114.224.060.844]
Palivizumab [D12.776.124.790.651.114.224.060.860]
Panitumumab [D12.776.124.790.651.114.224.060.864]
Ranibizumab [D12.776.124.790.651.114.224.060.868]
Trastuzumab [D12.776.124.790.651.114.224.060.875]
Ustekinumab [D12.776.124.790.651.114.224.060.937]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Globulins [D12.776.377]
Serum Globulins [D12.776.377.715]
Immunoglobulins [D12.776.377.715.548]
Antibodies [D12.776.377.715.548.114]
Antibodies, Monoclonal [D12.776.377.715.548.114.224]
Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Abciximab [D12.776.377.715.548.114.224.200.125]
Adalimumab [D12.776.377.715.548.114.224.200.250]
Alemtuzumab [D12.776.377.715.548.114.224.200.375]
Basiliximab [D12.776.377.715.548.114.224.200.407]
Bevacizumab [D12.776.377.715.548.114.224.200.438]
Brentuximab Vedotin [D12.776.377.715.548.114.224.200.469]
Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
Cetuximab [D12.776.377.715.548.114.224.200.750]
Daclizumab [D12.776.377.715.548.114.224.200.766]
Denosumab [D12.776.377.715.548.114.224.200.782]
Gemtuzumab [D12.776.377.715.548.114.224.200.790]
Inotuzumab Ozogamicin [D12.776.377.715.548.114.224.200.794]
Ipilimumab [D12.776.377.715.548.114.224.200.798]
Natalizumab [D12.776.377.715.548.114.224.200.813]
Nivolumab [D12.776.377.715.548.114.224.200.829]
Omalizumab [D12.776.377.715.548.114.224.200.844]
Palivizumab [D12.776.377.715.548.114.224.200.860]
Panitumumab [D12.776.377.715.548.114.224.200.864]
Ranibizumab [D12.776.377.715.548.114.224.200.868]
Trastuzumab [D12.776.377.715.548.114.224.200.875]
Ustekinumab [D12.776.377.715.548.114.224.200.937]
Expand All
Collapse All
Bevacizumab
Preferred
Concept UI
M0443627
Registry Number
2S9ZZM9Q9V
Scope Note
An anti-VEGF humanized murine monoclonal antibody. It inhibits
VEGF RECEPTORS
and helps to prevent
PATHOLOGIC ANGIOGENESIS
.
Terms
Bevacizumab
Preferred Term
Term UI
T000874953
Date
02/09/2015
LexicalTag
NON
ThesaurusID
NLM (2016)
Mvasi
Narrower
Concept UI
M000638103
Registry Number
0
Terms
Mvasi
Preferred Term
Term UI
T000934808
Date
10/17/2017
LexicalTag
TRD
ThesaurusID
NLM (2019)
Bevacizumab-awwb
Narrower
Concept UI
M000638602
Registry Number
0
Terms
Bevacizumab-awwb
Preferred Term
Term UI
T000935363
Date
10/30/2017
LexicalTag
NON
ThesaurusID
NLM (2019)
Avastin
Narrower
Concept UI
M0446630
Registry Number
0
Terms
Avastin
Preferred Term
Term UI
T534903
Date
03/10/2003
LexicalTag
TRD
ThesaurusID
NLM (2003)
page delivered in 0.15s
